Etiqueta: john’s hopkins
-
Autologous Cell Therapies Do Not Represent a Public Health Risk and Should Not Be Regulated Like Drugs
SevOne Founder and Stem Cell Institute patient, Michael Phelan discusses what’s financially at stake for scientists, universities, drug companies, and the FDA who oppose autologous stem cell therapy and lobby for patients’ own stem cells to be regulated as drugs. VIEW FULL ARTICLE Forbes interview with Michael Phelan from Feb 2013: One Man’s Reluctant Tour…